Patient Thrives One Month After Experimental Pig Heart Transplant: A Glimpse of Hope
Patient Thrives One Month After Experimental Pig Heart Transplant: A Glimpse of Hope
| Meet larry faucette, the pioneer of the pig heart transplant, and Dr.Bartley Griffith, the sugeon behind the groundbreaking procedure (University of Maryland Medicine) |
In a remarkable turn of medical innovation, a Maryland man has defied the odds, thriving one month after undergoing an experimental pig heart transplant, leaving doctors astonished as the patient shows no signs of organ rejection or infection.
Dr. Muhammad Mohiuddin, the co-director of the cardiac xenotransplantation program at the University of Maryland School of Medicine, shared an update on the patient's remarkable progress. Lawrence Faucette, a 58-year-old Navy veteran and a devoted father, had been grappling with end-stage heart disease when he arrived at the University of Maryland Medical Center (UMMC).
In a candid revelation, Dr. Bartley Griffith, a professor of surgery at the University of Maryland School of Medicine, disclosed that Faucette was considered ineligible for a traditional human heart transplant due to pre-existing peripheral vascular disease and complications related to internal bleeding.
 |
| Lawrence faucette and his wife, ann, before the life-changing transplant surgery (University of Maryland Medicine) |
Faucette, well aware of the gravity of his condition, embraced the experimental xenotransplant as his last beacon of hope. "My only real hope left is to go with the pig heart, the xenotransplant," he conveyed from his hospital room in the days preceding the surgery. His wife, Ann Faucette, echoed his sentiments, saying, "We have no expectations other than hoping for more time together, as simple as sitting on the front porch and having coffee together."
The U.S. Food and Drug Administration (FDA) granted emergency approval for Faucette's surgery on September 15, employing the "compassionate use" pathway, which is reserved for patients facing severe or life-threatening conditions with no alternative treatment options.
The intricate procedure, although similar to traditional human heart transplants, required surgical adjustments to accommodate some anatomical differences. Pigs were chosen as organ donors for xenotransplants due to their organ size, physiological metabolism, and immune system's similarity to that of humans.
 |
| UMMC Surgeons in action: Groundbreaking pig heart transplant Procedure - lawrence faucette's journey" (University of Maryland Medicine) |
Before the pig heart could be transplanted, scientists had to "knock out" three genes in the donor pig to prevent organ rejection by the recipient's antibodies. Furthermore, six human genes responsible for immune acceptance of the pig heart were inserted into the genome, and one additional gene was deactivated to curtail excessive growth of pig heart tissue. A total of 10 unique gene edits were made in the donor pig.
Acknowledging the inherent risks of the procedure, Dr. Mohiuddin highlighted the potential for acute heart rejection and complications during surgery, especially given the patient's critical condition before the transplant.
Faucette's surgery marked only the second instance of this experimental procedure, following David Bennett's successful surgery in 2022. Unfortunately, Bennett later succumbed to heart failure. While the transplant appeared successful, his demise was attributed to various factors, including his poor health and an extended stay on a heart-lung bypass machine.
The UMMD research team, led by Dr. Griffith and Dr. Mohiuddin, invested five years perfecting the surgical technique on non-human primates before proceeding with the first human surgeries.
Moving forward, Faucette's doctors are meticulously monitoring his recovery, which is expected to be more comprehensive than that of traditional heart transplant patients. Rehabilitation, including physical therapy, is a key focus in helping him regain his strength.
The success of Faucette's groundbreaking surgery holds the potential to usher in clinical trials, which are essential prerequisites for FDA approval of xenotransplants for the broader patient population in need of organ transplants.
While commendable efforts are made to promote organ donation, Dr. Griffith emphasized the persisting global shortage of organs for transplant. Xenotransplantation, which could offer a virtually limitless supply of organs for transplant, represents an encouraging avenue to address this critical issue. It holds the promise of not only serving as a bridge to human organ transplants but also as a long-term solution for patients who have no alternative options.
